Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Deborah Mudali, Jaison Jeevanandam & Michael K. Danquah. (2020) Probing the characteristics and biofunctional effects of disease-affected cells and drug response via machine learning applications. Critical Reviews in Biotechnology 40:7, pages 951-977.
Read now
Read now
Serge Jabbour. (2017) Durability of response to dapagliflozin: a review of long-term efficacy and safety. Current Medical Research and Opinion 33:9, pages 1685-1696.
Read now
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2017) Dapagliflozin for the treatment of type 1 diabetes mellitus. Expert Opinion on Investigational Drugs 26:7, pages 873-881.
Read now
Read now
Hui Shao, Suodi Zhai, Dajin Zou, Mohammed Umer Mir, Nadine K. Zawadzki, Qian Shi, Shuqian Liu & Lizheng Shi. (2017) Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current Medical Research and Opinion 33:2, pages 359-369.
Read now
Read now
Kelly F Bell, Arie Katz & John J Sheehan. (2016) Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies. Risk Management and Healthcare Policy 9, pages 231-241.
Read now
Read now
Stanley S Schwartz & Arie Katz. (2016) Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin. Diabetes, Metabolic Syndrome and Obesity 9, pages 71-82.
Read now
Read now
Markus F Scheerer, Roland Rist, Orm Proske, Annika Meng & Karel Kostev. (2016) Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes, Metabolic Syndrome and Obesity 9, pages 337-345.
Read now
Read now
Neil Skolnik, Harmony Bonnes, Helen Yeh & Arie Katz. (2016) Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C. Postgraduate Medicine 128:4, pages 356-363.
Read now
Read now
Jay H Shubrook, Babak Baradar Bokaie & Sarah E Adkins. (2015) Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy 9, pages 5793-5803.
Read now
Read now
Matthew R. Weir, Irina Kline, John Xie, Robert Edwards & Keith Usiskin. (2014) Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Current Medical Research and Opinion 30:9, pages 1759-1768.
Read now
Read now
William N Washburn & Simon M Poucher. (2013) Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opinion on Investigational Drugs 22:4, pages 463-486.
Read now
Read now
Julia Kenkre, Tricia Tan & Stephen Bloom. (2013) Treating the obese diabetic. Expert Review of Clinical Pharmacology 6:2, pages 171-183.
Read now
Read now
Articles from other publishers (35)
Rania M. Salama, Rodaina H. Ahmed, Alaa A. Farid, Basma A. AbdElSattar, Radwa M. AbdelBaset, Merna E. Youssef & Sara A. El Wakeel. (2023) Gastroprotective effect of dapagliflozin in ethanol-induced gastric lesions in rats: Crosstalk between HMGB1/RAGE/PTX3 and TLR4/MyD88/VEGF/PDGF signaling pathways. International Immunopharmacology 115, pages 109686.
Crossref
Crossref
Mariavittoria D’Acierno, Roberta Resaz, Anna Iervolino, Rikke Nielsen, Donato Sardella, Sabrina Siccardi, Vincenzo Costanzo, Luciano D’Apolito, Yoko Suzumoto, Daniela Segalerba, Simonetta Astigiano, Alessandra F. Perna, Giovambattista Capasso, Alessandra Eva & Francesco Trepiccione. (2022) Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b. Journal of the American Society of Nephrology 33:10, pages 1864-1875.
Crossref
Crossref
Yustika Sari, Dono Indarto & Brian Wasita. (2022) The Effects of Star Fruit (Averrhoa carambola Linn.) Extract on Body Mass Index, Fasting Blood Glucose, and Triglyceride Levels in Male Rats with Obesity and Type 2 Diabetes Mellitus. Open Access Macedonian Journal of Medical Sciences 10:A, pages 744-751.
Crossref
Crossref
Sangita Swapnasrita, Aurélie Carlier & Anita T. Layton. (2022) Sex-Specific Computational Models of Kidney Function in Patients With Diabetes. Frontiers in Physiology 13.
Crossref
Crossref
Hongju Wu & Vecihi Batuman. 2022. Diabetes and Kidney Disease. Diabetes and Kidney Disease
601
635
.
Kazuo Shimizu, Hideki Fujikura, Nobuhiko Fushimi, Toshihiro Nishimura, Kazuya Tatani, Kenji Katsuno, Yoshikazu Fujimori, Shinjiro Watanabe, Masahiro Hiratochi, Takeshi Nakabayashi, Noboru Kamada, Koichi Arakawa, Hidemasa Hikawa, Isao Azumaya & Masayuki Isaji. (2021) Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor. Bioorganic & Medicinal Chemistry 34, pages 116033.
Crossref
Crossref
Shanshan Hu, Xun Deng, Yanjiao Ma, Zhilei Li, Yuhang Wang & Yong Wang. (2020) Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied Health Economics and Health Policy 19:1, pages 69-79.
Crossref
Crossref
Prashant S. Devrukhakar & M. Shiva Shankar. (2020) Degradation Pathway Proposal, Structure Elucidation, and In Silico Toxicity Prediction of Dapagliflozin Propane Diol Hydrolytic Degradation Products. Chromatographia 83:10, pages 1233-1245.
Crossref
Crossref
Constantin Berger & Daniela Zdzieblo. (2020) Glucose transporters in pancreatic islets. Pflügers Archiv - European Journal of Physiology 472:9, pages 1249-1272.
Crossref
Crossref
ManashPratim Baruah, BM Makkar, VikrantB Ghatnatti & Kaushik Mandal. (2019) Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism 23:1, pages 140.
Crossref
Crossref
Mamdouh A. Oraby, Mohammed F. El-Yamany, Marwa M. Safar, Naglaa Assaf & Hamdy A. Ghoneim. (2019) Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomedicine & Pharmacotherapy 109, pages 910-920.
Crossref
Crossref
Soad L. Kabil & Nevertyty M. Mahmoud. (2018) Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. European Journal of Pharmacology 828, pages 135-145.
Crossref
Crossref
Stephanie Fraser & Sarah Osgood. (2017) Current practices and future outlook on the integration of biomarkers in the drug development process. Bioanalysis 9:22, pages 1827-1837.
Crossref
Crossref
Natalia G. Vallianou, Eleni Geladari & Christos E. Kazazis. (2017) SGLT-2 inhibitors: Their pleiotropic properties. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11:4, pages 311-315.
Crossref
Crossref
Tuba M. Ansary, Yoshihide Fujisawa, Asadur Rahman, Daisuke Nakano, Hirofumi Hitomi, Hideki Kobara, Tsutomu Masaki, Jens M. Titze, Kento Kitada & Akira Nishiyama. (2017) Responses of renal hemodynamics and tubular functions to acute sodium–glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Scientific Reports 7:1.
Crossref
Crossref
M. Joubert & Y. Reznik. (2017) Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure. Diabetes & Metabolism 43, pages 2S34-2S38.
Crossref
Crossref
Tushar Madaan, Mohd. Akhtar & Abul Kalam Najmi. (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences 93, pages 244-252.
Crossref
Crossref
W. J. Wan Seman, N. Kori, S. Rajoo, H. Othman, N. Mohd Noor, N. A Wahab, N. Sukor, N. Mustafa & N. A. Kamaruddin. (2016) Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes, Obesity and Metabolism 18:6, pages 628-632.
Crossref
Crossref
C. D. Sjöström, M. Hashemi, J. Sugg, A. Ptaszynska & E. Johnsson. (2015) Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes, Obesity and Metabolism 17:8, pages 809-812.
Crossref
Crossref
Eva M. Vivian. (2015) Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. American Journal of Health-System Pharmacy 72:5, pages 361-372.
Crossref
Crossref
Theodosios D. Filippatos, Evangelos N. Liberopoulos & Moses S. Elisaf. (2014) Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 6:1, pages 29-41.
Crossref
Crossref
M.C. Thomas, K. Jandeleit-Dahm & F. Bonnet. (2014) Beyond Glycosuria: Exploring the intrarenal effects of SGLT-2 inhibition in diabetes. Diabetes & Metabolism 40:6, pages S17-S22.
Crossref
Crossref
Agata Ptaszynska, Kristina M. Johnsson, Shamik J. Parikh, Tjerk W. A. de Bruin, Anne Marie Apanovitch & James F. List. (2014) Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events. Drug Safety 37:10, pages 815-829.
Crossref
Crossref
Matt Hrapchak, Bachir Latli, Xiao-Jun Wang, Heewon Lee, Scot Campbell, Jinhua J. Song & Chris H. Senanayake. (2014) Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13. Journal of Labelled Compounds and Radiopharmaceuticals 57:12, pages 687-694.
Crossref
Crossref
Naoto Terami, Daisuke Ogawa, Hiromi Tachibana, Takashi Hatanaka, Jun Wada, Atsuko Nakatsuka, Jun Eguchi, Chikage Sato Horiguchi, Naoko Nishii, Hiroshi Yamada, Kohji Takei & Hirofumi Makino. (2014) Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice. PLoS ONE 9:6, pages e100777.
Crossref
Crossref
Merlin C. Thomas. (2014) Renal effects of dapagliflozin in patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism 5:3, pages 53-61.
Crossref
Crossref
S. Goring, N. Hawkins, G. Wygant, M. Roudaut, R. Townsend, I. Wood & A. H. Barnett. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 433-442.
Crossref
Crossref
S. Grandy, A. M. Langkilde, J. E. Sugg, S. Parikh & C. D. Sjöström. (2014) Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. International Journal of Clinical Practice 68:4, pages 486-494.
Crossref
Crossref
K. Tatarkiewicz, C. Polizzi, C. Villescaz, L. J. D'Souza, Y. Wang, S. Janssen & D. G. Parkes. (2013) Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. Diabetes, Obesity and Metabolism 16:4, pages 376-380.
Crossref
Crossref
Pitchai Balakumar, Karupiah Sundram & Sokkalingam A. Dhanaraj. (2014) Dapagliflozin: Glucuretic action and beyond. Pharmacological Research 82, pages 34-39.
Crossref
Crossref
Uta Kunter. 2014. SpringerReference Innere Medizin. SpringerReference Innere Medizin
1
17
.
Vecihi Batuman. 2014. Diabetes and Kidney Disease. Diabetes and Kidney Disease
241
250
.
Ankur Jindal, Mariana Garcia-Touza, Nidhi Jindal, Adam Whaley-Connell & James R. Sowers. (2013) Diabetic Kidney Disease and the Cardiorenal Syndrome. Endocrinology and Metabolism Clinics of North America 42:4, pages 789-808.
Crossref
Crossref
Mark Tirmenstein, Thomas E. Dorr, Evan B. Janovitz, Deborah Hagan, Lynn M. Abell, Joelle M. Onorato, Jean M. Whaley, Michael J. Graziano & Timothy P. Reilly. (2013) Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor. International Journal of Toxicology 32:5, pages 336-350.
Crossref
Crossref
Anthony H. Barnett. (2013) Complementing Insulin Therapy to Achieve Glycemic Control. Advances in Therapy 30:6, pages 557-576.
Crossref
Crossref